suministro del principio activo denominado "AVAPRITINIB 50 MG COMPRIMIDO ORAL" para el HospitalUniversitario de Gran Canaria Dr. Negrín.
TED · 418587-2026Award noticeawardedNo deadline given
Buyer
NameDirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín
CountryES
Published2026-06-18
Deadline—
Who already wins at this buyer
Firms with recorded awards from Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| IPSEN PHARMA, S.A.U. | 1 | €595,637 | 2026-06-18 |
| SWEDISH ORPHAN BIOVITRUM S.L | 1 | €403,705 | 2026-05-27 |
| IPSEN PHARMA, S.A. | 1 | €396,028 | 2026-05-11 |
| MERCK SHARP & DOHME ESPAÑA, S.A. | 1 | €332,277 | 2026-05-11 |
| ROCHE FARMA, S.A. | 1 | €305,648 | 2026-07-13 |
CPV codes
33690000 Medical equipment & pharmaceuticalsDescription
El objeto del contrato viene determinado por el suministro del principio activo denominado "AVAPRITINIB 50 MGCOMPRIMIDO ORAL" para el Hospital Universitario de Gran Canaria Dr. Negrín.Dicho objeto corresponde al código 33690000-3 (Medicamentos diversos), de la nomenclatura Vocabulario Común deContratos (CPV) de la Comisión Europea.
Similar tenders
Closest by meaning — across languages, via embeddings.